Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Radiation Oncology cung cấp cho các bạn kiến thức về ngành y đề tài: Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy. | Davies et al. Radiation Oncology 2011 6 114 http content 6 1 114 RADIATION ONCOLOGY RESEARCH Open Access Phospho-ERK and AKT status but not KRAS mutation status are associated with outcomes in rectal cancer treated with chemoradiotherapy 3 3 Janine M Davies Dimitri Trembath Allison M Deal William K Funkhouser Benjamin F Calvo Timothy Finnegan6 Karen E Weck3 Joel E Tepper2 7 and Bert H O Neil1 2 Abstract Background KRAS mutations may predict poor response to radiotherapy. Downstream events from KRAS such as activation of BRAF AKT and ERK may also confer prognostic information but have not been tested in rectal cancer RC . Our objective was to explore the relationships of KRAS and BRAF mutation status with p-AKT and p-ERK and outcomes in RC. Methods Pre-radiotherapy RC tumor biopsies were evaluated. KRAS and BRAF mutations were assessed by pyrosequencing p-AKT and p-ERK expression by immunohistochemistry. Results Of 70 patients mean age was 58 36 stage II 56 stage III and 9 stage IV. Responses to neoadjuvant chemoradiotherapy 64 limited 19 major and 17 pathologic complete response. 64 were KRAS WT 95 were BRAF WT. High p-ERK levels were associated with improved OS but not for p-AKT. High levels of p-AKT and p-ERK expression were associated with better responses. KRAS WT correlated with lower p-AKT expression but not p-ERK expression. No differences in OS residual disease or tumor downstaging were detected by KRAS status. Conclusions KRAS mutation was not associated with lesser response to chemoradiotherapy or worse OS. High p-ERK expression was associated with better OS and response. Higher p-AKT expression was correlated with better response but not OS. Keywords Rectal cancer KRAS analysis phosphoERK phosphoAKT radiation response Background The most common genetic mutation in all cancers is the RAS mutation occurring in 30 of cancers 1 . The RAS family of genes K- H- and N-RAS transduce and likely integrate messages from growth factor
